Project Grant K99HL186058
Award Date 5/8/26
Completion Date 4/30/28
Dollars Obligated $145K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $865,286 to Boston Children's Hospital (The Children's Hospital Corporation) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with a completion date of June 30, 2029. This research initiative will produce a high-resolution spatiotemporal lineage map of cardiac development by integrating advanced lineage tracing, spatial, and single-cell...
- Federal Grant Award Summary Boston Children's Hospital received a $267,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with completion anticipated by July 31, 2027. The award funds research to identify shared molecular mechanisms underlying congenital heart disease (CHD) and neurodevelopmental delay and disability (NDD) by characterizing dysregulated gene expression in...
- Federal Project Grant Award Summary Boston Children's Hospital received an $833,594 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with a completion date of May 31, 2029. The grant funds basic research investigating the pro-regenerative potential of PONTIN (an AAA+ ATPase protein) in cardiac tissue, with the objective of identifying druggable pathways to stimulate heart...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a Project Grant totaling $865,694 (awarded June 5, 2025; completion date April 30, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on neuropilin-2 (NRP2) signaling and lymphatic function. The research focuses on understanding how NRP2, a transmembrane receptor in lymphatic endothelial cells, functions as a dynamic regulator of...
- Summary This National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research project grant (CFDA 93.837) awarded $866,279 to Boston Children's Hospital, with performance in Boston, MA, supports research investigating coordinated protein synthesis and degradation mechanisms during neonatal heart regeneration. The research will generate scientific insights into how neonatal cardiomyocytes maintain protein homeostasis and rapidly adapt to ischemic injury—a regenerative capacity...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a Project Grant of $117,525 on July 7, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cellular adaptation mechanisms in response to one-carbon metabolism perturbation. The research focuses on understanding how erythroid cells respond to folate deficiency through a combination of genome-wide CRISPR screening, RNA sequencing, and molecular...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $511,987 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 27, 2025, with a completion date of May 31, 2029. This award funds a comparative research study investigating the molecular mechanisms of lamin A/C (LMNA)-related dilated cardiomyopathy, a severe form of adult-onset heart disease. The...
- Federal Grant Award Summary Boston Children's Hospital received a $279,644 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion scheduled for August 31, 2027. The grant funds research to develop and validate time to return of spontaneous circulation (ROSC) as a novel primary outcome measure for pediatric in-hospital cardiac arrest (P-IHCA) clinical trials. The research...
- Federal Grant Award Summary Boston Children's Hospital received a $5.96 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with completion expected May 31, 2030. The grant funds "Optimizing HCT Outcomes: A Multi-Omic Investigation," a research initiative focused on improving outcomes for patients undergoing hematopoietic stem cell transplantation (HCT), a critical...
- Federal Project Grant Award Summary Boston Children's Hospital received a $809,162 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with a completion date of June 30, 2030. This award supports research investigating pulmonary ionocyte function and development using induced pluripotent stem cell (iPSC)-derived airway epithelium models. The research aims to advance...